Emanuel Marques

6PUBLICATIONS
9CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)AllergyAutoimmunityDermatology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 27, 2025
Prognostic Biomarkers for Anti-PD-1 Monoclonal Antibodies in the First Line Treatment of Advanced Melanoma.

Marek Pásek, Emanuel Marques, Vojtěch Tretera

|Jun 07, 2024
Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma.

Marek Pásek, Emanuel Marques, Jiří Švec

|Feb 26, 2024
Risk of squamous cell carcinoma in patients with hidradenitis suppurativa treated with anti-TNF-alpha-Results from a 12-year multicentric observational prospective study.

Alžběta Smetanová, Marek Pásek, Emanuel Marques

|Feb 04, 2021
Corticosteroid rescue therapy in relapsing hidradenitis suppurativa treated with adalimumab.

M Arenbergerova, S Gkalpakiotis, E Marques

|Dec 10, 2020
Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha.

E Marques, P Arenberger, A Smetanová

|Sep 23, 2020
Epidemiology of moderate-to-severe psoriasis: a comparison between psoriasis patients treated with biological agents, conventional systemic drugs and topical agents.

Emanuel Marques, Zoltán Paluch, Petr Boháč

Pageof 1

Frequent Collaborators

4 joint publications

Monika Arenbergerová

3 joint publications

Marek Pásek

3 joint publications

Petr Arenberger

1 joint publications

S Gkalpakiotis